What is Generate Biomedicines, Inc. 's change in AP?

Generate Biomedicines, Inc. (GENB) reported change in AP of $3.75M in Q1 2026.

What does change in AP mean?

Increase or decrease in amounts owed to suppliers — a key working capital component affecting operating cash flow.

Generate Biomedicines, Inc. GENB Change in AP

Change in AP at other companies

MYR GroupMYRG

$15.72M+301%

RepligenRGEN

$5.92M+188%

Galaxy Digital Inc. Class A Common StockGLXY

-$14.21M+5.7%

Versant Media Group, Inc. VSNT

$127M+485%

Loar HoldingsLOAR

$5.25M+172%

Kymera TherapeuticsKYMR

$8.82M+125%

Other financials

Income statement

See full

Revenue$7.2M-18.1%

Operating income-$64.1M-33.1%

Net income-$61.4M-47.4%

EPS (diluted)-$1.07+34.0%

Balance sheet

See full

Cash & equivalents$160.6M-27.2%

Total debt$65.6M—

Total equity$514.8M+209%

Total assets$625.7M—

Cash flow

See full

Operating cash flow-$80.4M-51.2%

CapEx$3.8M+403%

Free cash flow-$84.2M-56.1%

Valuation

See full

Market cap$1.86B—

Enterprise value$1.76B—

Returns & leverage

See full

Debt / equity0.1×—

Current ratio9.2×—

Where this comes from

Reported directly by Generate Biomedicines, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccountsPayable.

The official record: Generate Biomedicines, Inc. ’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Generate Biomedicines, Inc. 's change in ap.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Generate Biomedicines, Inc. 's change in AP?: Generate Biomedicines, Inc. (GENB) reported change in AP of $3.75M in Q1 2026.
What does change in AP mean?: Increase or decrease in amounts owed to suppliers — a key working capital component affecting operating cash flow.